Background. Endothelial dysfunction in cardiovascular (CV) diseases is closely associated with increases in plasma level of shed membrane microparticles (MPs) of endothelial origin. As arterial damage is a major contributor to CV mortality, we examined whether or not increases in endothelial microparticles (EMPs) circulating levels could predict outcome in patients with end-stage renal disease (ESRD). Methods. This prospective pilot study conducted in a community hospital (median follow-up: 50.5 months), included 81 stable haemodialysed ESRD patients (59 6 14 years; 63% male). Platelet-free plasma obtained 72 h after last dialysis was analysed by flow cytometry, and MPs cellular origin identified as endothelial (CD311CD41ÀMPs; EMPs), platelets (CD311CD411MPs) or erythrocyte (CD235a1MPs). The main outcome measures were global and CV mortality (fatal myocardial infarction, stroke, acute pulmonary oedema and sudden cardiac death). Results. Non-survivors (n ¼ 24) were older (P < 0.001) and characterized by higher levels of EMPs (P < 0.01) and high-sensitivity C-reactive protein (P < 0.05) and lower diastolic blood pressure (P < 0.001). Kaplan-Meier analysis demonstrated significantly higher probability of all-cause (P < 0.001) and CV mortality (P < 0.0001) between the lower and upper EMPs tertiles. Multivariate Cox regression analysis demonstrated that baseline EMP levels independently predicted all-cause [hazard ratio (HR) ¼ 21.7, 95% confidence interval (CI): 4.23-111.18 per log EMPs/lL; P ¼ 0.0002] and CV mortality (HR ¼ 20.0, 95% CI: 3.86-103.5) per log EMPs/lL; P < 0.0004) after adjustment for confounding factors. EMPs baseline level was a stronger predictor of poor outcome than classical risk factors. Conclusion. This study demonstrates that increased plasma levels of EMPs is a robust independent predictor of severe CV outcome in end-stage renal failure patients.
Introduction
Endothelial dysfunction or activation is a systemic disorder and a key variable in the pathogenesis of atherosclerosis and its complications, resulting in a chronic inflammatory process accompanied by loss of antithrombotic factors and increases in vasoconstrictor and prothrombotic products, in addition to abnormal vascular reactivity [1] . Furthermore, endothelial dysfunction is associated with and predicts increased rate of adverse cardiovascular (CV) events [2] . The severity of endothelial dysfunction closely associates with increases in circulating levels of membrane microparticles (MPs) of endothelial origin in several CV diseases, supporting the concept that endothelial MP (EMP) plasma level is a surrogate marker of endothelial dysfunction [3] [4] [5] [6] . MPs are plasma membrane vesicles shed from apoptotic or activated cells and identified in plasma and inflammatory tissues [7] . Circulating MPs originate mostly from platelets, but MPs from other cell types (erythrocytes, leucocytes or endothelial cells) have been also found in plasma [4, 8] . Furthermore, circulating levels of MPs increase in patients with CV diseases and could contribute to the general endothelial dysfunction observed in these patients by impairing endothelial NO release [4, 9, 10] .
Patients with end-stage renal disease (ESRD) have a high incidence of CV events, accounting for a large part of the mortality observed in this population [11] . Furthermore, uraemic patients rapidly develop systemic endothelial dysfunction [12] , which represents a risk factor for subsequent complications [13] . In addition, endothelial dysfunction is closely associated with increased circulating levels of EMPs in ESRD [4] . Therefore, we conducted a prospective pilot study to identify the impact of baseline EMPs on global mortality and on fatal major adverse CV events in a cohort of haemodialysed patients.
Material and methods
This prospective pilot study included 81 patients with ESRD from the Fleury-Mérogis haemodialysis (HD) centre. Patients were enrolled during 14 months starting November 2003 and were followed up until December 2009 (Table 1 ). Eligibility criteria were (i) HD therapy for !3 months, (ii) no clinical CV complication (myocardial infarction, stroke, emergent coronary revascularization, severe peripheral artery disease requiring revascularization and/or amputation) during the 6-month period preceding entry and (iii) patients agreed to participate in the follow-up study, which was approved by our Institutional Review Board and adhered to the Declaration of Helsinki. Patients were excluded from the study if they presented at time of screening any of the following conditions: occurrence of an acute major CV events (stroke, myocardial infarction, acute heart failure, acute limb ischaemia) within the 6 months preceding screening, presence of a chronic inflammatory disease, presence of infectious disease and presence of cancer or a non-anaemic haematological disorder. Furthermore, n ¼ 4 patients underwent kidney transplantation and were censored at the time of transplantation.
Patients were dialysed three times per week using high permeability membranes AN69 and polysulphone. Seventy-six had a native arteriovenous fistula. HD duration was individually tailored (4-6 h per session) to control body fluids and blood chemistries and to achieve a Kt/V >1.2 (1.46 AE 0.13). The dialysate was prepared with double osmosis ultrapure water and delivered by a system including bicarbonate delivery, adjustable sodium concentration and controlled ultrafiltration. Patients were regularly prescribed iron and erythropoietin (darbepoietin). Some patients received adjunctive anti-hypertensive therapy (angiotensin-converting enzyme inhibitor and/or calcium-channel blocker; n ¼ 35), beta-blockers (n ¼ 21) or statin therapy (n ¼ 15). Dry weight was targeted in every patient to achieve a normotensive oedema-free state at each dialysis session.
Blood chemistries
Blood chemistries, determined on samples drawn prior to MP measurement, included (Table 1) haemoglobin, low-density lipoprotein cholesterol, triglycerides, serum albumin, serum high-sensitivity C-reactive protein (hs-CRP), blood lipids, serum parathormone (PTH1-84), serum phosphates and Ca 21 .
Framingham risk scores (FRS) and European SCORE calculation
Framingham sex-specific equations were used to calculate Framingham risk scores (FRS) for general CV disease [14] over 10 years. The European SCORE (estimation of the 10-year CV death risk) was calculated using the SCORE risk charts [15] . Risks were calculated using systolic blood pressure, total and high-density lipoprotein cholesterol, age, current smoking status, diabetes and use of anti-hypertensive medications [14, 15] .
Microparticles analysis
Platelet-free plasma samples (PFP) were obtained from citrated whole blood drawn from the fistula-free arm 72 h after the last dialysis and prior to the next dialysis session as previously described [4] . Briefly, the whole blood was first centrifuged during 15 min at 500 g in order to obtain platelet-rich plasma, then this PRP was centrifuged during 5 min at 14 000 g to pellet the platelets and obtain PFP. MP baseline levels and cellular origins were measured using flow cytometry analyses (Coulter EPICS X; Beckman Coulter, Marseille, France), by two independent examiners unaware of the subject status [4] . 21 (26) 5 (21) 16 (28) a Continuous variables with normal distribution are expressed as mean 6 SD and variables with non-normal distribution are expressed as median (range). Spearman correlations were not significant between EMP levels and erythropoietin (r ¼ 0.050; P ¼ 0.660), ACE inhibitors (r ¼ À0.0026; P ¼ 0.862), statins (r ¼ 0.127; P ¼ 0.394) or beta-blockers (r ¼ À0.040; P ¼ 0.811) in the n ¼ 81 included patients. BMI, body mass index; BP, blood pressure; ACE, angiotensin-converting enzyme; deceased versus alive. *P < 0.05. **P < 0.01. ***P < 0.001.
One hundred microlitres of this PFP solution were incubated with different fluorochrome-labelled antibodies or their respective isotypic immunoglobulins (Beckman Coulter). We used anti-CD31-phycoerythrin (PE; 20 lL per test), anti-CD41-PC5 (10 lL per test), anti-CD144-PE (20 lL per test) and anti-CD11b-PC5 (20 lL per test), antibodies obtained from Beckman Coulter. MPs that expressed phosphatidylserine were labelled using fluorescein-conjugated Annexin V solution (20 lL per test; Roche Diagnostics, Mannheim, Germany) in the presence of CaCl2 (5 mM) according to the recommendation of the supplier. Diluted solutions and fluorescence antibodies were incubated at room temperature for 30 min with regular shaking. An equal volume of Flowcount calibrator beads (Beckman Coulter) then was added, and samples were analysed. MP concentration was assessed by comparison with calibrator Flowcount beads (Beckman Coulter; 10 lm diameter) with a predetermined concentration. Sample analysis was stopped after the count of 20 000 events at medium flow rate setting.
Events with a 0.1-to 1-lm diameter were identified in forward scatter and side scatter intensity dot representation, gated as MP, and then plotted on one-or two-colour fluorescence histograms. MPs were defined as elements that had a size ranging from 0.1 lm to 1 lm and were positively labelled by specific antibodies. Several specific MP populations were defined, as previously reported [4] 
.
Clinical end point assessment
During follow-up, major adverse cardiovascular events (MACE) and deaths were accurately recorded and reviewed by a panel of three physicians. All available medical information was obtained, including hospital records, as part of the study record. CV death included fatal myocardial infarction, stroke, acute pulmonary oedema and sudden death. MACE included either fatal or non-fatal CV events (acute coronary syndromes, stroke, acute pulmonary oedema and arrhythmias).
Statistical analysis
Data are expressed as mean AE SD or median and range or according to the normality of distribution. Quantitative variables with non-normal distribution were log transformed to achieve normal distribution before correlations analysis. Mann-Whitney, Student's t-test and v 2 tests were used for comparison of continuous and categorical variables among the population. The repeatability of EMPs measurement was prospectively assessed in a subgroup of patients, using Spearman correlations and the Bland-Altman plot analysis [16] .
The primary analyses concerned Cox proportional hazards model and the survival curves. Patients were censored the day of death or transplantation. Prognostic factors of survival were identified with the use of the univariable Cox proportional hazards regression model. The assumption of proportional hazards over the time and assumption of linearity were verified before the analyses and were met by all covariates. Due to high co-linearity between several variables, data reduction procedure was used to determine the final Cox model. The number of variables in the model was reduced using automatic backward stepwise selection algorithm. Variables with a significant association to outcome, as assessed by a P-value <0.05 in univariate analysis, were entered in the multivariate model. The variable with the strongest association was entered first, followed by the next strongest, until all variables related to the outcome are entered into the model. Any variable that has been entered but is no longer significant after other variables have been added to the model is sequentially deleted. Survival was estimated by the Kaplan-Meier product-limit method and compared by the Mantel (log-rank) test. Differences were considered significant at P <0.05. Receiver operator characteristics (ROC) curve analyses were done to estimate the sensitivity and specificities. Statistical analysis was performed with NCSS 7.0 software (J. Hintze, Kaysville, UT). Table 1 shows the clinical and biochemical characteristics of the 81 patients included in the study. The median follow- . Statistical analysis of the repeatability of EMPs determination (assessed in n ¼ 41 patients with stable haematocrit; a mean delay of 115 (3-296) days between blood samples collection) revealed that EMP measures were reproducible with time ( Figure 1) .
Results

Patient characteristics
During the follow-up period, 24 deaths (27%) were recorded, of which 17 were of CV causes (sudden cardiac death, n ¼ 5; acute pulmonary oedema, n ¼ 6; myocardial infarction, n ¼ 4; stroke, n ¼ 2). Deceased patients had greater levels of circulating EMPs, moderate increase in hs-CRP and serum calcium and were significantly older than survivors (Table 1 ). There was no difference regarding baseline CV risk factors, but moderate increases in Framingham score, mainly influenced by older age (Table 1) 
Outcome and prognostic impact of circulating MPs
The cumulative event rates for composite CV and all-cause mortality are shown in Figures 2 and 3 . The Kaplan-Meier curves for EMPs, separated in tertiles, showed significant differences in CV and all-cause mortality for circulating EMPs (P < 0.01 and P < 0.00001, respectively; log-rank test; Figure 2A ). However, no significant differences were observed for circulating PMPs (P ¼ 0.863 and P ¼ 0.186, respectively; Figure 2B ).
According to univariate Cox analysis for all-cause mortality, the significant covariates retained were age, mean blood pressure, history of CV diseases, FRS and EMPs levels ( Univariate Cox analysis showed that the significant covariates associated with CV mortality were age, history of CV disease, mean blood pressure, hs-CRP, Framingham score and EMP levels ( Table 3 ). In multivariate adjusted Cox model, age (HR ¼ 1.09, 95% CI: 1.02-1.16 per year; P < 0.0084) and EMPs (HR ¼ 20.0, 95% CI: 3.86-103.5 per log EMP/lL; P < 0.0004) were the only independent predictors of CV mortality (Table 3) .
Comparable findings were observed in n ¼ 41 patients who had repeated measurement of EMPs where the analysis included the second measure of EMPs the follow-up corresponding to elapsed time from the second measure to end of follow-up (data not shown). Moreover, we observed the same relationships between EMPs and outcome in a subgroup of patients (n ¼ 55) who had endothelial CD1441 EMP levels measurement at baseline, in addition to CD311CD41À EMPs determination (not shown). Finally, we recorded n ¼ 35 fatal and nonfatal MACE during follow-up and found out that EMP levels, age and history of CV disease were independent predictors of events (Table 4) .
ROC curves were analysed for specificity and sensitivity analyses of putative predictors of global and CV mortality (Figure 3) . The areas under the curve (AUCs) were 70.6 AE 6.8 (age), 87.6 AE 6.0 (EMPs), 62.4 AE 8.4 (PMPs) and 68.0 AE 9.2 (FRS) for CV mortality. The optimal usable cut-off value of EMP level was 1190 events/ lL, with 63% sensitivity and 82% specificity for global death prediction (positive predictive value ¼ 60% and negative predictive value ¼ 82%). Moreover, the optimal usable cut-off value of EMPs level was 1040 events/lL, with 83% sensitivity and 75% specificity for CV death prediction (positive predictive value ¼ 46% and negative predictive value ¼ 94%). 
Discussion
This prospective pilot study performed in patients with ESRD and stable CV condition demonstrate that high plasma EMPs levels are an independent and robust predictor of all-cause and CV mortality, whereas such potential was not revealed for MPs from other cell types.
CV disease is a major cause of death in patients with ESRD and the projected life expectancy of these patients Fig. 3 . ROC curves of baseline MPs levels, using patients' outcome as reference. Unlike PMP levels (green line), baseline EMP levels (red line) were strongly associated to CV outcome. EMP demonstrated a larger AUC than age (blue line) and Framingham score (black line) for CV mortality prediction. is much lower than the general population [11, 17] . Mortality in patients with ESRD can be predicted by many factors, including increases in inflammatory mediators [18] [19] [20] , asymmetric dimethylarginine plasma levels [21] , sympathetic activity, catecholamines or arterial stiffness [22] . One possible common denominator between these different markers of mortality in ESRD is endothelial activation and dysfunction. Endothelial dysfunction is a clinical syndrome that is associated with and predicts increased rate of adverse CV events [1, 23, 24] . Clinical studies demonstrate that endothelial function is abnormal in patients with ESRD [12, 13, 23, 25, 26] but the underlying mechanism is not fully understood. Inflammatory cytokines, hyperhomocysteinaemia and increased levels of asymmetric dimethylarginine could promote endothelial activation, leading to dysfunctional endothelial cells with decreased bioavailability of NO [27] . Loss of NO vasoprotective effect would impact on vascular function and structure, thus contributing together with other factors to increase in vascular stiffness [28, 29] . Endothelial inflammation and activation stimulates the shedding of MPs [30] . In addition, uraemic toxins and defects in endothelial NO bioavailability favour EMP release [30, 31] . The composition of EMPs might also be affected by the stimuli triggering their generation. Circulating levels of EMPs are a surrogate marker of endothelial dysfunction in ESRD patients, in patients with coronary artery diseases and in obese subjects [4] [5] [6] 32] . Furthermore, we and others previously reported that EMPs, generated either in vivo or in vitro, can interact with endothelial cells to decrease NO production, increase local apoptosis or blunt cell proliferation rate, suggesting that circulating EMPs might accentuate preexisting endothelial dysfunction [4, 33] . Moreover, EMPs also have significant impact on inflammation, coagulation or angiogenesis and might thus interfere with the other protagonists of disrupted vascular homeostasis to favour the development of atherosclerosis and its complications (including thrombosis) [7] . We show here for the first time that circulating EMP levels are a robust predictor of all-cause and CV mortality in ESRD. This conclusion was not reached for plasma MPs from platelet origin. These results are in-line with data recently obtained from patients with coronary artery disease and heart failure [34] [35] [36] . We also observed that hs-CRP levels, previously reported as a predictor of allcause and CV mortality in ESRD [37] , were modestly but significantly increased in non-survivors when compared to survivors. However, multivariate analysis failed to demonstrate in the present study that hs-CRP levels were associated with mortality. Nevertheless, despite the limited size of the sample, circulating EMPs appeared to be a more powerful independent predictor of MACE in asymptomatic ESRD subjects than classical risk factors or Framingham risk score. These results might be explained by the potential deleterious biological effects of the circulating EMPs than can confer an additional risk in subjects with high levels of this biomarker.
Taken all together, the present results demonstrate that EMP measurement was reproducible, independently related to CV outcome, presented a stronger relationship to the pre-defined study end points than other risk factors in multivariate analysis and showed a larger AUC in ROC analysis than Framingham risk score.
Study limitations
The number of patients included in the present prospective pilot study could explain the weak relationship between some of the classical risk factors (such as hs-CRP) and outcome. However, the population investigated was large enough to highlight the strong and independent prognostic value of circulating EMPs. Our findings might be affected by the low prevalence of diabetes among our patients, a comorbidity that specifically promotes CV diseases but also potentially associates with increased EMP formation [5, 38, 39] . The diabetes prevalence in our cohort reflects this condition frequency in the French population. This low prevalence limits the confounding role of diabetes on the results and strengthens the relationship observed between EMPs and CV outcome but could influence its applicability to populations with high diabetes prevalence. Concerns might also be raised regarding the use of the Framingham score as a tool for CV risk evaluation in patients with ESRD since this score results from primary prevention data. Although ESRD patients have a higher incidence of adverse CV events than the general population, few data are available regarding a specific CV risk predictor. The successful use of FRS in ESRD patients and its relationship to other classical risk factor such as endothelial dysfunction has been reported [40] .
Perspectives
High levels of EMPs are a strong independent predictor of CV events and global mortality in haemodialysed patients with ESRD. Detection of EMPs in human plasma could help identifying asymptomatic patients at higher risk of developing CV diseases and thus would lead to better risk stratification and more cost-effective preventive therapies. Finally, these findings support the hypothesis that levels of circulating EMPs might be an important risk marker for CV disease in chronic renal failure. Larger multi-centre studies should determine in the future whether or not circulating EMPs are of prognostic value in other populations with an increased risk of CV complications.
